Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Feb 24;142:83–122. doi: 10.1016/j.antiviral.2017.02.014

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Published by Elsevier B.V.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — HCV genome structure and schematic view of HCV combination drugs. (A) HCV genome structure. In the length of approximately 3011 amino acids, the HCV genome codes for three structural proteins (core, E1, E2) and seven non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B) whose amino acid positions are mapped accordingly. The 5′ untranslated region (5′ UTR) and the 3′ untranslated region (3′ UTR) are also indicated. Approved antiviral agents directly target to NS3/4A, NS5A, and NS5B for effective inhibition of HCV replications. (B) A total of 15 NS3/4A, NS5A, NS5B compounds plus ritonavir are displayed in the circle. Colored links in the center visualize 13 drug combinations: (i) boceprevir (Victrelis^®) + PegIFNα/RBV, (ii) telaprevir (Incivek^®) + PegIFNα/RBV, (iii) sofosbuvir (Sovaldi^®) + PegIFNα/RBV, (iv) simeprevir (Olysio^®) + PegIFNα/RBV, (v) ledipasvir + sofosbuvir (Harvoni^®), (vi) ombitasvir + paritaprevir + ritonavir + dasabuvir (Viekira Pak™), (vii) ombitasvir + paritaprevir + ritonavir (Technivie™), (viii) daclatasvir (Daklinza™) + sofosbuvir (Sovaldi^®), (ix) elbasvir + grazoprevir (Zepatier™), (x) sofosbuvir + velpatasvir (Epclusa^®), (xi) vaniprevir (Vanihep^®) + PegIFNα/RBV, (xii) asunaprevir (Sunvepra^®) + daclatasvir (Daklinza^®), (xiii) voxilaprevir + velpatasvir + sofosbuvir. Notably, (i) to (x) were approved by the FDA and could be used with or without ribavirin; (xi) and (xii) were approved in Japan; and (xiii) is currently under assessment by the FDA. Two discontinued drugs boceprevir and telaprevir are indicated by green texts. This figure shows that HCV combination drugs are composed of anti-HCV inhibitors from different drug classes.

HHS Vulnerability Disclosure